
Opinion|Videos|February 24, 2025
Dosing and Titration Considerations
Panelists discuss how pharmacists must carefully consider factors like age-related changes in drug metabolism, comorbid conditions, concurrent medications, fall risk, and individual patient response when dosing and titrating VMAT2 inhibitors in older adults, typically recommending a "start low, go slow" approach while closely monitoring for both efficacy and adverse effects.
Advertisement
Episodes in this series

Video series above is prompted by the following:
- What key factors should pharmacists consider when dosing or titrating VMAT2 inhibitors for older patients?
Advertisement
Related to this article

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.

An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.

A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Glucose Monitoring: Timing Makes Every Reading Count
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
5



